Nomenclature
Short Name:
TYRO3
Full Name:
Tyrosine-protein kinase receptor TYRO3
Alias:
- BYK
- DTK
- Tif
- EC 2.7.1.112
- EC 2.7.10.1
- RSE
- SKY
Classification
Type:
Protein-tyrosine kinase
Group:
TK
Family:
Axl
SubFamily:
NA
Specific Links
Structure
Mol. Mass (Da):
96,905
# Amino Acids:
890
# mRNA Isoforms:
1
mRNA Isoforms:
96,905 Da (890 AA; Q06418)
4D Structure:
Monomer and homodimer. Interacts with GAS6
1D Structure:
3D Image (rendered using PV Viewer):
PDB ID
Subfamily Alignment
Domain Distribution:
Kinexus Products
Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Ubiquitinated:
K582.
N-GlcNAcylated:
N63, N191, N230, N240, N283, N366, N380.
Serine phosphorylated:
S307, S428, S466, S543, S682, S794, S818, S835, S869, S889.
Threonine phosphorylated:
T427.
Tyrosine phosphorylated:
Y681+, Y685+, Y686+, Y828, Y849.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
100
1053
29
1016
6
66
17
33
21
226
19
270
70
736
106
602
43
452
25
462
3
32
74
27
38
400
39
617
50
526
51
898
29
307
17
253
11
113
117
125
10
104
44
168
44
460
235
535
13
136
41
222
30
319
18
265
19
198
39
316
4
44
16
32
6
58
296
79
17
175
29
240
6
60
106
75
44
463
109
505
57
602
38
671
16
169
42
186
15
160
37
214
23
242
32
239
18
194
37
474
94
989
65
2720
7
72
43
105
12
129
31
216
17
181
32
186
20
209
28
155
32
333
24
336
95
998
36
1584
8
79
72
166
54
566
62
606
7
74
35
75
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
32.2
46.8
99.5
94.9
95.2
99
-
-
92
-
-
93
90.7
93
94.5
-
-
-
88.8
91.7
90
88.8
91.9
90
-
-
-
33.6
37
-
67.1
78.8
70
58.5
73.2
62
48.9
63.6
53
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Binding Proteins
Examples of known interacting proteins
hiddentext
| No. | Name – UniProt ID |
|---|---|
| 1 | GAS6 - Q14393 |
| 2 | PIK3R1 - P27986 |
| 3 | PROS1 - P07225 |
| 4 | SRC - P12931 |
| 5 | FYN - P06241 |
| 6 | YES1 - P07947 |
Regulation
Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Inhibitors
For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
| Compound Name | KD, Ki or IC50 (nM) | PubChem ID | ChEMBL ID | PubMed ID |
|---|
Disease Linkage
General Disease Association:
Infectious disease
Specific Diseases (Non-cancerous):
Ebola virus; Marburg virus
Comments:
TYRO3 has been identified as a cell entry factor for Ebola and Marburg viruses.
Comments:
TYRO3 may also be a potential therapeutic target in breast cancer.
Gene Expression in Cancers:
TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Barrett's esophagus epithelial metaplasia (%CFC= -63, p<0.031); Cervical epithelial cancer (%CFC= +86, p<0.048); Clear cell renal cell carcinomas (cRCC) (%CFC= -49, p<0.095); Ovary adenocarcinomas (%CFC= +63, p<0.062); Pituitary adenomas (aldosterone-secreting) (%CFC= +77, p<0.04); and Uterine leiomyomas (%CFC= +125, p<0.054).
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.07 % in 24447 diverse cancer specimens. This rate is only -6 % lower and is very similar to the average rate of 0.075 % calculated for human protein kinases in general.
Frequency of Mutated Sites:
None > 3 in 20,637 cancer specimens
Comments:
Only 4 deletions, and no insertions or complex mutations are noted on the COSMIC website.